KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Biology / 2016 / Cilt: 40 - Sayı: 5

Cancer stem cells: lessons learned from the leukemic stem cells

Ayten KANDİLCİ
Sayfa
1012–1017
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This minireview summarizes the current view on cancer stem cells, and particularly leukemic stem cells, and their potential role in the initiation, maintenance, and therapy resistance of cancer.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Cancer is the second cause of death in Turkey and the frequency of cancer deaths increased from 12% in 2002 to 21% in 2009 ( Özkan et al., 2013).
📊
Temel Bulgular & Veri:To win the war on cancer, we certainly need to apply well-planned prevention policies, given that it is caused mostly by environmental factors, and to develop more effective therapies.
💡
Sonuç & Katkı:This minireview summarizes the current view on cancer stem cells, and particularly leukemic stem cells, and their potential role in the initiation, maintenance, and therapy resistance of cancer.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2002 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Cancer is the second cause of death in Turkey and the frequency of cancer deaths increased from 12% in 2002 to 21% in 2009 ( Özkan et al., 2013). To win the war on cancer, we certainly need to apply well-planned prevention policies, given that it is caused mostly by environmental factors, and to develop more effective therapies. To achieve a cure for the disease, it is crucial to understand the cellular and molecular mechanisms leading to cancer and to therapeutically target all the factors playing a role in the initiation, progression, maintenance, and relapse of the disease, preferably in the form of personalized therapy. One of the biggest challenges faced during the diagnosis and treatment of tumors, especially those arising from tissues composed of heterogeneous cell populations such as hematopoietic tissues, is to find the cell of origin or the cancer-initiating cell. Knowing the cell of origin can help in dissecting the normal features of the target cell from its abnormal cancerous form; moreover, this knowledge provides insight into the early events leading to a malignant transformation and eventually shapes the treatment protocols. Initial and ongoing studies in leukemia elegantly showed how to identify the cell of origin (or the stem cells of cancers) and how to calculate their frequency and evolution during disease progression. This minireview summarizes the current view on cancer stem cells, and particularly leukemic stem cells, and their potential role in the initiation, maintenance, and therapy resistance of cancer.

🔖

Bu Makaleye Atıf Yap

KANDİLCİ, A. (2022). Cancer stem cells: lessons learned from the leukemic stem cells. Turkish Journal of Biology, Cilt: 40 - Sayı: 5, 1012–1017. https://ajindex.com/articles/600447

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Blair A, Hogge DE, Sutherland HJ (1998). Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. Blood 92: 4325-4335.
  2. Bonnet D, Dick JE (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
  3. Carella C, Bonten J, Sirma S, Kranenburg TA, Terranova S, Klein-Geltink R, Shurtleff S, Downing JR, Zwarthoff EC, Liu PP et al. (2007). MN1 overexpresion is an important step in the development of inv(16) AML. Leukemia 21: 1679-1690.
  4. Christensen JL, Weissman IL (2001). Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. P Natl Acad Sci USA 98: 14541-14546.
  5. Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, Bhatia R (2011). Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118: 5565-5572.
  6. Clarkson BD (1969). Review of recent studies of cellular proliferation in acute leukemia. Natl Cancer I Monogr 30: 81-120.
  7. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL (2003). Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Gene Dev 17: 3029-3035.
  8. Dick JE (2008). Stem cell concepts renew cancer research. Blood 112: 4793-4807.
  9. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J et al. (2011). Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17: 1086-1093.
  10. Gawad C, Koh W, Quake SR (2014). Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. P Natl Acad Sci USA 111: 17947-17952.
  11. Gilliland DG, Jordan CT, Felix CA (2004). The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program: 80-97.
  12. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806.
  13. Greaves M (2010). Cancer stem cells: back to Darwin? Semin Cancer Biol 20: 65-70.Grove CS, Vassiliou GS (2014). Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Model Mech 7: 941-951.
  14. Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, Fung S, Schlenk RF, Dohner K, Hinrichsen T, Rudolph C et al. (2007). MN1 overexpression induces acute myel